Crinetics (CRNX)’ treatment of congenital adrenal hyperplasia, generic name atumelnant, was granted FDA orphan designation, according to a post to the agency’s site.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharma’s Earnings Call: Progress Amid Challenges
- Crinetics Pharmaceuticals: A Promising Buy with Strategic Initiatives and Upcoming Milestones
- Crinetics price target lowered to $86 from $90 at Citizens JMP
- Crinetics Pharmaceuticals Reports Q2 2025 Financial Results
- Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch